No Prescription |
 |
 | ||
|
Prescription Drugs 15 |
|
| ||
No Prescription » Prescription Drugs 15
Seroflo Rotacap with Rotohaler Advair SINEMET Generic Carbidopa Levodopa Singulair Generic Montelukast sodium Sterineb Respules Atrovent Respules Strong Heart For Large Dogs 23 45kgs Generic Heartgard Plus Strong Heart For Medium Dogs 12 22kgs Generic Heartgard Plus Strong Heart For Small Dogs Upto 11kgs Generic Heartgard Plus STUGIL Generic Cinnarizine Dompridone Suminat Auto Injection Imigran Injection Symbicort Turbuhaler Generic Budesonide Formoterol Synthroid Generic Levothyroxine Systane Eye Drops Generic Polyethylene Glycol
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|